Beyond the beginner version
The introductory explanation is that cannabinoids are compounds that bind to receptors in the body and produce effects. That is accurate and it is not very useful, because it does not explain why CBD does not get you high, why regular use stops working as well, or why two products with identical THC content can feel different.
This piece goes one level deeper. It is about signalling, ratios and the gap between what the research supports and what product marketing claims.
How binding actually works
THC is a partial agonist at CB1 and CB2 receptors. “Agonist” means it activates the receptor; “partial” means it activates it less than fully, no matter how much you supply. That ceiling matters: it is one reason cannabis does not produce the lethal respiratory depression that full agonists such as opioids can, and it also explains why extremely high doses produce diminishing additional euphoria but increasing side effects.
CBD behaves differently. It has very low affinity for CB1 and CB2 and works mainly through other mechanisms: it inhibits the enzyme FAAH, which breaks down anandamide, thereby raising endocannabinoid levels indirectly; it acts on serotonin receptors including 5-HT1A; and it influences TRP channels involved in pain and inflammation. It also appears to act as a negative allosteric modulator at CB1, meaning it changes the receptor’s response to THC rather than competing with it directly.
That last point explains the common consumer report that CBD softens an over-strong THC experience. It is not simply dilution; the pharmacology is genuinely different.
Ratios matter more than absolute amounts
Two products can each contain 20% total cannabinoids and behave entirely differently.
- 20:1 THC to CBD is a typical recreational flower, and will produce a full psychoactive effect.
- 1:1 THC to CBD usually feels noticeably milder than the THC number implies, because CBD modulates the response.
- 1:20 THC to CBD is a CBD-dominant product with minimal intoxication.
This is why reading a THC figure alone is a poor guide to strength. The same logic applies to minor cannabinoids: a flower with a meaningful CBG fraction often feels different in character from one without, even at identical THC content.
Tolerance: what is actually happening
Regular exposure to THC downregulates CB1 receptors — the cell reduces the number available on its surface — and desensitises the ones that remain. The practical result is that the same dose produces less effect, and more is needed for the same result.
Two important details follow. First, downregulation is reversible: a break of one to two weeks restores most sensitivity, which is why tolerance breaks work. Second, tolerance is partly cross-modal. Because Delta-8 also acts at CB1, tolerance built on one carries over to the other, though not perfectly.
CBD does not produce tolerance in the same way, because it is not primarily a CB1 agonist.
The entourage effect: what the evidence supports
The claim is that cannabinoids, terpenes and flavonoids interact synergistically, so a full-spectrum product produces effects that the sum of its isolated parts would not.
What supports it: several studies have found that whole-plant extracts produce effects at doses where isolated THC does not, and that specific terpenes interact with cannabinoid receptors in laboratory models. The best-known example is the finding that CBD modulates THC’s effects rather than simply adding to them.
What weakens it: much of the terpene research is in vitro or at concentrations far above what a person inhales, and controlled human trials comparing full-spectrum with isolate at matched THC doses are scarce and small. The honest position is that the effect is plausible, partly supported, and oversold.
None of that means full-spectrum flower is not worth choosing. It means the reason to choose it is the whole experience — flavour, ritual, the range of compounds — rather than a proven synergy multiplier.
The claims that outrun the evidence
Three categories of claim are worth treating sceptically.
“Cannabinoid X treats condition Y.” There is good evidence for cannabis in chronic pain, chemotherapy-induced nausea, and specific epilepsy syndromes, and licensed medicines exist for the latter two. For almost everything else, the evidence is preliminary, mixed or absent. CBN for sleep is a good example: it is widely sold on that basis and supported mostly by anecdote.
Precise dosing claims. “10mg of this will do exactly that” ignores enormous individual variation in absorption, metabolism and tolerance. The same edible dose can be mild for one person and overwhelming for another.
Terpene “profiles” sold as pharmacology. A myrcene-heavy strain being “for sleep” is a reasonable heuristic drawn from consumer reports. It is not a clinical finding, and human trials on inhaled terpene effects are thin.
What this means practically
- Read the whole certificate, not the THC line. Total cannabinoids, ratios, minor cannabinoids and terpenes all carry information.
- Expect tolerance, and plan for it. Breaks of a week or two are the simplest intervention available.
- Do not chase potency. Because THC is a partial agonist, doubling the dose does not double the effect but does roughly double the side effects.
- Use CBD deliberately. If a batch is too strong, a CBD-dominant product alongside it is a rational response rather than a folk remedy.
- Treat mechanism claims as hypotheses. Including most of the ones in this article that are still under investigation.
The uncomfortable finding
One of the more important results in cannabis research is also one of the least convenient for the strain-based market: in 2022, a genetic analysis of commercial cannabis published in Nature Plants found that the plants labelled indica and sativa did not cluster into two genetic groups corresponding to those labels. The labels are marketing categories with a long history, not botanical classification.
The same applies to cannabinoid ratios. THC is a partial agonist, and the ceiling it imposes means that doubling the dose does not double the effect. It roughly doubles the side effects.
What is still genuinely unknown
Most of the minor cannabinoids have barely been studied in humans. The interactions between terpenes and cannabinoids are poorly characterised outside a lab dish. Individual variation in response is large and largely unexplained. And the long-term effects of regular high-potency use are, by definition, not yet visible in a market that has only existed in this form for a few years.
Understanding cannabinoids honestly means holding both facts at once: the pharmacology is real and well characterised at the receptor level, and the consumer-level claims built on top of it are often running well ahead of the data.
Frequently Asked Questions
What does it mean that THC is a partial agonist?
It activates CB1 receptors but not to their maximum, no matter how much is present. That ceiling limits how intense the effect can get, which is why very high doses produce more side effects rather than proportionally more euphoria.
How does CBD interact with THC?
CBD has low affinity for cannabinoid receptors and acts mainly by inhibiting anandamide breakdown, influencing serotonin and TRP channels, and acting as a negative allosteric modulator at CB1. In practice it often makes a THC experience feel milder than the THC figure suggests.
Why does my tolerance keep increasing?
Regular THC exposure downregulates CB1 receptors and desensitises the remaining ones, so the same dose does less. It reverses with a break of one to two weeks, which is the most effective intervention available.
Is the entourage effect proven?
Partly. Some studies support whole-plant extracts behaving differently from isolated THC, and CBD clearly modulates THC. But controlled human trials at matched doses are scarce, and many terpene claims rest on laboratory work at concentrations far above real-world exposure.
Do cannabinoids affect prescription medication?
They can. Cannabinoids interact with CYP enzymes that metabolise many drugs, so clearance rates can change. This matters most with blood thinners, some antidepressants and epilepsy medication. Ask a pharmacist rather than relying on general guidance.